Search the Newsreel

American Century entities (NYSE: MCS) disclose 5.0% beneficial stake in The Marcus Corporation

American Century Investment Management, Inc., American Century Companies, Inc., and the Stowers Institute for Medical Research have collectively disclosed a 5.0% beneficial ownership stake in The Marcus Corporation (NYSE: MCS), totaling 1,197,597 shares as of June 30, 2026. The entities report sole voting and …

Huatai Securities Co Ltd Class H (6886) Q4 2023 Earnings Report - Results, Call & Slides

Fort Baker Capital discloses 4.2% ANSC stake in Schedule 13G/A filing (ANSC)

Fort Baker Capital Management LP, along with Steven Patrick Pigott and Fort Baker Capital, LLC, has reported a beneficial ownership of 1,379,630 Class A ordinary shares in Agriculture & Natural Solutions Acquisition Corp (ANSC). This stake represents 4.2% of the outstanding Class A shares, …

What Could Drive Canadian Utilities (TSX:CU) Shares From Here?

Securitize Corp. Common Stock (NYSE:SECZ) Stock Quote

This article provides a stock quote for Securitize Corp. Common Stock (NYSE:SECZ), showing its current price, trading volume, and recent performance. It also includes headlines about the company's Q2 2026 earnings, which reported a 5% revenue decrease year-over-year. The article concludes with frequently asked …

Marcus Corp (MCS) investors disclose 2.19M-share, 9.2% ownership position

Orbis Investment Management Limited and Allan Gray Australia Pty Ltd have disclosed a combined beneficial ownership of 2,189,129 shares of Marcus Corp (MCS) common stock, representing a 9.2% stake in the company. The filing, a Schedule 13G/A, indicates that Orbis holds the majority with …

Kratos (KTOS) Is Up 9.4% After Raising 2026 Outlook And Securing New Missile Defense Work

In early August 2026, Kratos Defense & Security Solutions reported second-quarter revenue of US$458.8 million and higher net income year-on-year, raised its 2026 revenue outlook to US$1.75–US$1.81 billion, and highlighted new defense work including Javelin seeker development and support for Japan's SPY-7 missile defense …

Docusign (NASDAQ:DOCU) Shares Down 4.6% - Here's Why

Docusign (NASDAQ:DOCU) shares dropped 4.6% in Friday trading, closing at $61.1550, despite the company beating quarterly earnings and revenue estimates. The decline follows recent analyst downgrades and price target reductions from firms like Wedbush, Wells Fargo, and BTIG Research, with the stock currently holding …

Oculis (NASDAQ:OCS) Price Target Cut to $20.00 by Analysts at JPMorgan Chase & Co.

JPMorgan Chase & Co. has reduced its price target for Oculis (NASDAQ:OCS) to $20.00 from $23.00, while maintaining an "overweight" rating. Despite this reduction and similar cuts by other firms, Oculis still holds a consensus "Moderate Buy" rating with an average price target of …

NextCure (NXTC): Squadron funds and partners disclose 1.6% equity stake

Squadron Master Fund LP and its related parties, including Squadron Capital Management, LLC, Matthew Sesterhenn, and William Blank, have disclosed a 1.6% equity stake in NextCure, Inc. through a SCHEDULE 13G/A SEC filing. This group beneficially owns 64,464 shares of NextCure common stock and …

Photocure Welcomes FDA Proposal to Initiate the Reclassification of Blue Light Cystoscopy Systems from Class III to Class II

OSLO, Norway, Aug. 14, 2026 /PRNewswire/ -- Photocure ASA (OSE: PHO), the Bladder Cancer Company, today announced that the U.S. Food and Drug Administration (FDA) has published a proposed order in the Federal Register to initiate the process of reclassifying cystoscopic systems intended as …

Curanex Pharmaceuticals Inc Q2 2026: Net income $(3.29M), EPS $(0.12) — 10-Q Summary

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $(3.29M) for Q2 2026, with a diluted loss per share of $(0.12), and no revenue as the company remains pre-revenue. This compares to a net loss of $(0.06M) in Q2 2025. The company completed a …

CURX: Net loss rose to $6.4M as R&D spending increased; cash shortfall raises going concern doubts

Curanex Pharmaceuticals Inc (CURX) reported a net loss of $6.4 million for the first half of 2026, primarily due to increased spending on R&D and administrative costs as its lead drug candidate progresses. The company faces significant going concern doubts as its current cash …

Marcus & Millichap Brokers $7 Million Sale of Retail, Office Property in Northern New Jersey

Marcus & Millichap has successfully brokered the $7 million sale of a 26,240-square-foot retail and office property in Livingston, New Jersey. Built in 1970, the property comprises 19 units, 75 parking spaces, and a newly constructed car wash, and was 92 percent leased at …

Conferencia de resultados del T2 de 2026 de Acumen Pharmaceuticals (ABOS): lectura de datos de ALTITUDE-AD prevista para finales de 2026

Acumen Pharmaceuticals (NASDAQ: ABOS) held its Q2 2026 earnings conference call, focusing on the upcoming Phase II ALTITUDE-AD trial results for sabirnetug, expected by late 2026. The company reported $110.2 million in cash and marketable securities, providing liquidity until early 2027, with a net …

Securitize Corp. 2Q 2026: No revenue or EPS presented — 10-Q Summary

Securitize Corp. did not report revenue, net income, or diluted EPS for the quarter ending June 30, 2026, as the public parent (PubCo) had no operations before its reverse recapitalization. The company began trading on the NYSE as SECZ on July 2, 2026, following …

Custom Truck One Source (CTOS) Q2 2026 Earnings Call Transcript

Cullen/Frost Bankers (NYSE:CFR) Hits New 12-Month High - What's Next?

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights

Cue Biopharma reported its second-quarter 2026 financial results, highlighting a significant increase in revenue due to a collaboration milestone and higher expenses related to the CUE-221 development program. The company also announced the submission of an IND for CUE-221 in food allergy applications, a …

Can Kratos Defense's $15B Opportunity Pipeline Sustain Growth Momentum?

Kratos Defense & Security Solutions, Inc. KTOS appears to be building a stronger foundation for sustained growth as increasing defense demand translates into new contract awards and a growing pipeline of potential opportunities. During the second quarter of 2026, the company generated $458.8 million …

Marcus & Millichap Brokers $5M Sale of Single-Tenant Retail Property in Alameda, California

Marcus & Millichap has facilitated the $5 million sale of a single-tenant retail property in Alameda, California. The 3,000-square-foot building is occupied by Peet’s Coffee & Tea under a 10-year lease with annual rent increases. Mark Mason of Marcus & Millichap represented the buyer, …

ICU Medical (ICUI) Insider Sells 5,417 Shares: VP, GM-Infusion Capital Daniel Woolson Reduces Stake

Daniel Woolson, VP, GM-Infusion Capital at ICU Medical Inc (ICUI), sold 5,417 shares of the company on August 13, 2026, bringing his total ownership to 17,062 shares. This transaction is part of a trend where insiders at ICU Medical have generally been selling more …

Cycurion Releases Q2 2026 Financial Results

Cycurion, Inc. (WAVS) reported its Q2 2026 financial results, showing a narrowed net loss of $4.0 million, or $0.41 per share, indicating improved profitability. Revenue for the quarter was $3.8 million, a slight decrease of 3.4% from Q2 2025, while the company continued to …

Custom Truck One Source (CTOS) Is Down 7.2% After Raising 2026 Revenue Outlook And Returning To Profitability – Has The Bull Case Changed?

Custom Truck One Source (CTOS) reported strong Q2 2026 results, returning to profitability and raising its full-year 2026 revenue guidance to US$2.10 billion to US$2.20 billion. Despite this positive outlook and projected high single-digit Q3 revenue growth, the stock experienced a 7.2% drop. The …

CTOS|Custom Truck One Source Inc|Price:10.437|Chg%:+0.176

Sell Alert: Daniel Woolson Cashes Out $982K In ICU Medical Stock

Daniel Woolson, VP at ICU Medical (NASDAQ: ICUI), recently sold 5,417 shares of the company's stock for a total transaction value of $982,264, as disclosed in an SEC filing. This insider transaction occurred on August 13, leading to a slight dip in ICU Medical's …

Cullen/Frost Bankers Inc stock hits all-time high at 170.34 USD

Cullen/Frost Bankers Inc. stock reached an all-time high of $170.34, demonstrating significant growth with a 36.66% increase over the past year. The company, which has a market cap of $10.54 billion and offers a 2.44% dividend yield with 33 years of consecutive dividend raises, …

$1000 Invested In Mercury System 10 Years Ago Would Be Worth This Much Today

An investment of $1000 in Mercury System (NASDAQ: MRCY) made 10 years ago would now be worth $4,732.18, demonstrating the power of compounded returns. The company has outperformed the market by 3.25% annually over the last decade, achieving an average annual return of 16.75%. …

Armistice Capital (ICCM) reports 300,332 IceCure Medical shares under shared control

Armistice Capital, LLC and Steven Boyd have reported beneficial ownership of 300,332 ordinary shares of IceCure Medical Ltd. (ICCM), representing 9.99% of the class, through a Schedule 13G SEC filing. These shares are held with shared voting and dispositive power. Armistice Capital acts as …

Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

OCUL|Ocular Therapeutix Inc|Price:9.890|Chg%:-0.210

This article provides detailed financial and analytical data for Ocular Therapeutix Inc (OCUL), including its live stock price, chart, news, and a comprehensive stock score. It covers key financial figures, performance over various periods, technical analysis, analyst ratings, and company profile. The data shows …

Cycurion earnings beat by $0.15, revenue topped estimates

Cycurion (NASDAQ: CYCU) reported a Q2 EPS of $-0.41, surpassing analyst estimates by $0.15, and revenue of $3.76M, which also topped consensus estimates. Despite this earnings beat, the company's stock price has significantly declined over the past three and twelve months. InvestingPro assesses Cycurion's …

Celcuity remains a Buy as FDA approval and strong trial data boost confidence in its cancer drug launch.

Celcuity Inc. has received a "Buy" rating following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its quick inclusion in NCCN Category 1 guidelines, which is expected to aid adoption. Despite high upfront commercial investments and a significant valuation, the company's strong cash …

Form 8K FEDERAL AGRICULTURAL MORTGAGE CORPORATION For: 14 August By Investing.com

This article reports that FEDERAL AGRICULTURAL MORTGAGE CORPORATION has filed a Form 8K on August 14. The filing is brief and primarily serves as a notification of the SEC document. The article includes general market data and related news but offers no further details …

Ganges Securities Q1 Results: Net profit falls 37% YoY to ₹8.08 lakh

Cycurion beats revenue & EPS estimates; lands $54.6M 10-year contract, gross margin jumps to 29.1%

Cycurion (CYCU) reported strong Q2 results, exceeding revenue and EPS estimates. The company secured a significant $54.6 million, 10-year contract and saw its gross margin increase substantially to 29.1%. Acquisitions also contributed to a boosted revenue run rate.